Non-alcoholic fatty liver disease and risk of incident type 2 diabetes: Role of circulating branched-chain amino acids

Novel NS5B resistance-associated substitution emerges under failing sofosbuvir/ledipasvir therapy

LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 To Accrue Contingent Interest

BURLINGTON, N.C. --(BUSINESS WIRE)--Sep. 11, 2019-- LabCorp® (NYSE: LH) announced today that for the period of Sept. 11, 2019 to March 10, 2020 , its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will, subject to the terms of the Zero Coupon Notes, accrue contingent cash

Covance Unveils New R&D Center in Shanghai

Inauguration Ceremony Highlights World-Class, Comprehensive Drug Development Capabilities and More Than Two Decades of Growth in China BURLINGTON, N.C. --(BUSINESS WIRE)--Sep. 10, 2019-- LabCorp® (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care,